Evidence map›Paper›PMID 30420853›Full record

ArticleFrontiers in immunology2018

Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity.

Onno J Arntz, Bartijn C H Pieters, Rogier M Thurlings, Mark H Wenink, Peter L E M van Lent, Marije I Koenders, Frank H J van den Hoogen, Peter M van der Kraan, Fons A J van de Loo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. In Vitro and In Vivo Anti-Arthritic Potential ofMolecules (Basel, Switzerland) · 2022
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Onno J ArntzDepartment of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands.
Bartijn C H PietersDepartment of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands.
Rogier M ThurlingsDepartment of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands.
Mark H WeninkDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands.
Peter L E M van LentDepartment of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands.
Marije I KoendersDepartment of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands.
Frank H J van den HoogenDepartment of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands.
Peter M van der KraanDepartment of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands.
Fons A J van de LooDepartment of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands.
Radboud University Medical Center · NLRadboud University Nijmegen · NLSint Maartenskliniek · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that mainly affects synovial joints. Validated laboratory parameters for RA diagnosis are higher blood levels of rheumatoid factor IgM (IgM-RF), anti-citrullinated protein autoantibodies (ACPA), C-reactive protein (CRP) levels and erythrocyte sedimentation rate (ESR). Clinical parameters used are the number of tender (TJC) and swollen joints (SJC) and the global patient visual analog score (VAS). To determine disease remission in patients a disease activity score (DAS28) can be calculated based on SJC, TJC, VAS, and ESR (or alternatively CRP). However, subtle and better predictive changes to follow treatment responses in individual patients cannot be measured by the above mentioned parameters nor by measuring cytokine levels in blood. As extracellular vesicles (EVs) play a role in intercellular communication and carry a multitude of signals we set out to determine their value as a biomarker for disease activity. EVs were isolated from platelet-free plasma of 41 RA patients and 24 healthy controls (HC) by size exclusion chromatography (SEC). We quantified the particle and protein concentration, using NanoSight particle tracking analysis and micro-BCA, respectively, and observed no differences between RA patients and HC. In plasma of 28 out of 41 RA patients IgM-RF was detectable by ELISA, and in 13 out of these 28 seropositive RA patients (RF

Indexed as

AdultAgedAged, 80 and overArthritis, RheumatoidBiomarkersBlood SedimentationC-Reactive ProteinExtracellular VesiclesFemaleHumansImmunoglobulin GImmunoglobulin MMaleMiddle AgedRheumatoid FactorSeverity of Illness IndexBiomarkersC-Reactive ProteinImmunoglobulin GImmunoglobulin MRheumatoid FactorC-reactive proteindisease activity score 28ESRextracellular vesiclesplasmarheumatoid arthritisrheumatoid factor IgM

Identifiers

PMID30420853
PMCPMC6215817
OpenAlexW2892401345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.